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Abstract
Background: Chondrosarcomas are malignant cartilage tumors that do not respond to traditional chemotherapy
or radiation. The 5-year survival rate of histologic grade III chondrosarcoma is less than 30%. An animal model of
chondrosarcoma has been established - namely, the Swarm Rat Chondrosarcoma (SRC) - and shown to resemble
the human disease. Previous studies with this model revealed that tumor microenvironment could significantly
influence chondrosarcoma malignancy.
Methods: To examine the effect of the microenvironment, SRC tumors were initiated at different transplantation
sites. Pyrosequencing assays were utilized to assess the DNA methylation of the tumors, and SAGE libraries were
constructed and sequenced to determine the gene expression profiles of the tumors. Based on the gene
expression analysis, subsequent functional assays were designed to determine the relevancy of the specific genes
in the development and progression of the SRC.
Results: The site of transplantation had a significant impact on the epigenetic and gene expression profiles of SRC
tumors. Our analyses revealed that SRC tumors were hypomethylated compared to control tissue, and that tumors
at each transplantation site had a unique expression profile. Subsequent functional analysis of differentially
expressed genes, albeit preliminary, provided some insight into the role that thymosin-b4, c-fos, and CTGF may
play in chondrosarcoma development and progression.
Conclusion: This report describes the first global molecular characterization of the SRC model, and it demonstrates
that the tumor microenvironment can induce epigenetic alterations and changes in gene expression in the SRC
tumors. We documented changes in gene expression that accompany changes in tumor phenotype, and these
gene expression changes provide insight into the pathways that may play a role in the development and
progression of chondrosarcoma. Furthermore, specific functional analysis indicates that thymosin-b4 may have a
role in chondrosarcoma metastasis.
Background
Chondrosarcoma is the second most common primary
bone malignancy [1] accounting for 25% of primary
bone sarcomas [2]. High grade lesions may be treated
with chemotherapy/radiation but chondrosarcomas are
usually not responsive to treatment [3,4] and, as a result,
the 5-year survival rate of histologic grade III chondro-
sarcoma is only 29% [5].
To attain a greater understanding of chondrosarcoma
tumorigenesis, a rat model of human chondrosarcoma
has been developed [6-8]. The model, known as the
Swarm rat chondrosarcoma (SRC), histologically resem-
bles the human tumor, indicating that the SRC is a sui-
table model to study chondrosarcoma [7,8]. Experiments
with the SRC tumors have demonstrated that transplan-
tation site can affect the malignancy of the tumor, and
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any medium, provided the original work is properly cited.more specifically, transplantation of the SRC tumor into
the tibia results in the formation of a higher grade
tumor compared to those derived from extraosseous
transplantation [8]. Since tumors grown at different
transplantation sites were initiated from the same pri-
mary tumor, the increase in malignancy observed with
the SRC tibia tumor is likely to result from the interac-
tion between the tumor and its microenvironment.
Although the SRC tumors have undergone extensive
histological characterization, no studies have examined
the effect that the transplantation site has on epigenetic
and gene expression profiles of the SRC tumors.
In this study, tumors were transplanted subcuta-
neously, or into the tibia of Sprague-Dawley rats. Subcu-
taneous tumor transplantation led to the formation of
significantly larger tumors than those tumors trans-
planted into the tibia. However, similar to previous SRC
experiments [8], transplantation of the SRC tumor into
the tibia resulted in the formation of more aggressive
tumors that were capable of invading the surrounding
bone tissue. SRC tumors were also detected in the lungs
of rats that had SRC tumor transplanted into the tibia,
but no SRC tumors were detected in the lungs of rats in
which tumor cells were injected subcutaneously.
Since changes in DNA methylation can significantly
impact SRC tumorigenesis [9], we performed epigenetic
analyses to determine the influence that the transplantation
environment had on tumor DNA methylation. The analysis
revealed that the tumor transplantation site could signifi-
cantly alter DNA methylation levels in the SRC tumors.
To complement the epigenetic analysis, global gene
expression profiles were generated for the SRC tumors
using SAGE (Serial Analysis of Gene Expression) [10].
This global gene expression analysis revealed that the
SRC tumors have gene expression profiles that are
unique to each transplantation site.
Analysis of the differentially expressed genes revealed
the pathways that are altered in the SRC tumors, and
subsequent functional analyses provided insight into the
role that specific genes, namely thymosin-b4, c-fos and
CTGF, may play in chondrosarcoma tumorigenesis.
Overall, our study highlights the influence of the micro-
environment on epigenetic and gene expression profiles
of SRC tumors. Such profiles provide an insight into the
biological pathways that may be affected by the micro-
environment, while underscoring the complex nature of
SRC tumorigenesis.
Methods
Ethics Statement
Animals were handled in strict accordance with good
animal practice as defined by the relevant national and/
or local animal welfare bodies, and all animal work was
approved by the Institutional Animal Care and Use
Committee (Children’s Memorial Research Center; pro-
tocol IACUC #2006-30).
Tumor induction and tissue harvesting
The SRC-JWS tumor line (Jeff Stevens, The University of
Iowa) was used for all transplantation studies. We demon-
strated by microscopy and immunohistochemistry that
tumors derived from transplantation of the SRC-JWS
tumor line are similar to conventional human chondrosar-
coma. Subcutaneous tumors were induced as previously
described [11,12]. Briefly, SRC-JWS tumor cells were iso-
lated from a subcutaneous SRC tumor, and 5 × 10
6 tumor
cells were injected subcutaneously into the lower lumbar
region of 4-week-old male Sprague-Dawley rats. In the
tibia transplantations, 5 × 10
6 SRC-JWS tumor cells were
injected into the proximal tibia as previously described [7].
Injection of SRC-JWS tumor cells into the tibia also
resulted in the formation of SRC tumors in the lungs.
Since this was observed even in the animals that had their
legs amputated within minutes of transplantation, the
observed SRC lung tumors were considered to result from
colonization of SRC tumor cells into the lungs, as opposed
to representing true lung metastases. The animals were
euthanized 35 days post tumor induction, and the tumor
tissues were frozen in liquid nitrogen immediately after
excision and stored at -80°C or placed in paraformalde-
hyde for histology. For histology, tumors were graded
based on previously described characteristics of human
chondrosarcoma [13,14]
Normal rat cartilage was obtained from femoral head
cartilage of 37-40 day old male Sprague-Dawley rats as
previously described [12].
Total RNA isolation
Total RNA was obtained from frozen tissues using TRI-
ZOL reagent (Life Technologies, Inc.). Total RNA was
treated with DNase (Promega #M6101), and subse-
quently treated with Proteinase K (Promega # 9PIV302).
Total RNA was further purified using RNeasy kit (Qia-
gen), and then used for subsequent reactions.
Sodium bisulfite treatment of DNA
Genomic DNA was obtained by digestion with protei-
nase K (Qiagen) followed by phenol/chloroform extrac-
tion, and was subjected to sodium bisulfite treatment to
modify unmethylated cytosines to uracil using the
‘CpGenome™DNA Modification Kit’ (Chemicon Interna-
tional, CA).
Pyrosequencing primer design
Satellite 1 primers were designed as previously described
[9]. Briefly, the rat genome sequence (rn4/version 3.4,
Nov. 2004), and the annotation for repetitive elements,
were obtained from the UCSC Genome Database.
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silico bisulfite conversion based on their genomic coor-
dinates in the UCSC database. Full-length Satellite 1
sequences were identified and used for alignment to
g e n e r a t eaS a t e l l i t e1n u c l e o t i d eb a s em a t r i x .Ar e g i o n
within Satellite 1 sequence with dense CpG dinucleo-
tides was selected for PCR primer design. An electronic
PCR was performed with the primers designed for rat
Satellite 1 sequences. A minimum of 137 distinct Satel-
lite I elements were predicted to be targeted in PCR
reactions with the primer set designed. Using a single
sequencing primer, a total of 3 CpG dinucleotides were
sequenced for each Satellite 1 element targeted. The
global methylation data generated was derived from a
minimum of 411 CpG dinucleotides in Satellite
elements.
SAGE library construction and data analysis
Poly (A)+ RNA was isolated from total RNA using
mRNA DIRECT Kit (Dynal) according to manufacturer’s
instructions. The poly(A)+ RNA and a biotinylated oligo
d(T) primer were used for cDNA synthesis according to
ap r e v i o u s l yd e s c r i b e dm e thod[15]. SAGE was carried
out as previously described [10].
Approximately 100,000 tags were derived from each
SAGE library. The initial sequencing files from each
SAGE library were processed with SAGE2000 (Johns
Hopkins University). For all analyses, each SAGE library
was normalized to 100,000 tags. SAGE libraries were
annotated using SAGEmap (http://www.ncbi.nlm.nih.
gov/projects/SAGE/). Mitochondrial tags were identified
using previously described annotation[16]. Genespring
was used to perform hierarchical clustering, and to gra-
phically represent the SAGE data. See Additional file 1
for complete SAGE data, Additional file 2 for the list of
differentially expressed SAGE tags, and Additional file 3
for the SAGE tag list of unique expression profiles.
Gene expression comparisons between SRC tumors:
Only genes with significantly different gene expression
were included in each analysis (z > 1.96; see “statistical
analysis”). SAGE tags also needed to have an expression
level of at least 25 in one tissue to be included in the
analysis. For the gene expression comparisons between
SRC tumors, condition trees illustrate the relationship
between the SAGE libraries with respect to the set of
differentially expressed genes.
All SAGE data is GEO compliant. The raw SAGE data
has been submitted to the GEO database. GSE1517 is
the accession number of the Swarm rat chondrosarcoma
SAGE data.
Real-Time quantitative PCR
Total RNA was isolated using Trizol; RNA was treated
with TURBO RNase-free DNase (Ambion Cat#
AM1907). Total RNA (1 μg) was used to make cDNA
with the iScript cDNA Synthesis kit (BioRad). Real time
PCR was performed with the iQ SYBR Green Supermix
(BioRad), and rat specific primers. Real time PCR pri-
mers were designed with Beacon Designer 6.0 (Premier
Biosoft International; Palo Alto CA). Thymosin-b4p r i -
mers were as follows: Forward: CACATCAAAGAAT-
CAGAACTAC; Reverse: TCTCAATTCCACCATCTCC.
C-fos primers were as follows: Forward: ACCACGAC-
CATGATGTTC; Reverse: AAGTTGGCACTAGA-
GACG. For SYBR green PCRs, 18S-rRNA was used as a
reference gene [17]. The 18 S rRNA primers were as
follows: Forward: GGGAGGTAGTGACGAAAAATAA-
CAAT; Reverse: TTGCCCTCCAATGGATCCT.
To measure the expression of the transgene construct,
primers were designed for the IRES (Internal Ribosome
Entry Sequence). The IRES sequence is present in all
expression vectors used within this report. The primer
sequence; MSCV-IRES-F: TCTGTAGCGACCCTTTGC
and MSCV-IRES-R: TTCCACAACTATCCAACTCAC.
18S-RNA was used as a reference gene for the analysis
of transgene expression.
The Pfaffl method was used to calculate the normal-
ized gene expression [18]. For each real time PCR analy-
sis the individual sample being examined was used as
the test sample in the Pfaffl method. The calibrator
sample, for the Pfaffl method, was an equal mixture of
cDNA from rat normal cartilage, SRC tumor, and/or
SRC cell line. All real time qPCR results are displayed
as a ratio of the target gene relative to the reference
gene, in a specific test sample, compared to the expres-
sion of the target gene relative to the reference gene in
the calibrator sample.
Thymosin-b4 and c-fos overexpression
Two vectors were made for the overexpression experi-
ments: MSCV-Thyb4-I-Puro and MSCV-cfos-I-Puro.
The expressions of Thyb4 and c-fos were driven by the
retroviral LTR, and the expression of the Puromycin
resistance gene was controlled by the IRES sequence.
The rat thymosin-b4 coding sequence was PCR ampli-
fied from a rat normal cartilage cDNA library clone
(UI-R-DY1-cns-1-12-0-UI) using the following primers:
Forward: CTCTGAGCAGGAATTCTCTCCTTGTTCG
CCCAGCTC, and Reverse: CTCAGTCAGTCTCGA
GTG CCCTGCCTTCTCTGACTG. The resulting thy-
mosin-b4 PCR product was digested with EcoRI and
XhoI. The digested PCR product was ligated to an
EcoRI-XhoI digested MSCV-I-Puro vector.
The rat c-fos coding sequence was PCR amplified
from a Swarm rat chondrosarcoma cDNA library clone
(UI-R-DZ0-crj-j-07-0-UI) using the following primers:
Forward: TCTACCCCTGGAATTCTCGCCGAGC
TTTGCCCAAAC, and Reverse: CTCAGTCAGTCTC
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fos PCR product was digested with EcoRI and XhoI.
The digested PCR product was ligated to an EcoRI-XhoI
digested MSCV-I-Puro vector.
A murine stem cell virus was prepared by transfecting
293T cells with three plasmids; pMSCV-I-Hygro vector
(for control cells: pMSCV-I-Hygro; for thymosin-b4:
MSCV-Thyb4-I-Puro; for c-fos expression MSCV-cFos-
I-Puro), pEQ-Pam3(-E) (which encodes retroviral gag
and pol) and pSRa-G (which encodes glycoprotein G
from Vesicular Stomatitis Virus) [19]. Forty-eight hours
post-transfection, media containing retroviral vector was
collected, aliquoted, frozen, and stored at -80°C. This
vector was then used to transduce the Swarm rat chon-
drosarcoma cell line (SRC-LTC (Long Term Culture)
[20], [obtained from Jeff W. Stevens, University of
Iowa]), in the presence of 5 μg/ml polybrene on three
successive days allowing the cells to recover in the
media used, generally overnight. Transduced cells were
selected by incubation with puromycin at a concentra-
tion of 3 μg/ml for 14 days. The overexpression of thy-
mosin-b4 and c-fos was confirmed following puromycin
selection.
Cell culture conditions
SRC-LTC cells were cultured in DMEM high glucose
(4.5 g glucose/ml) supplemented with 10% FBS and
Penicillin/Streptomycin. Cells were plated at 2.5. × 10
4
cells with 6 ml of media in a 25 cm
2 T flask. Cells were
grown until they became 80-90% confluent (6 days), and
at this time the cells were trypsinized and split.
Invasion assay
A Membrane Invasion Culture System (MICS) was used
to measure the in vitro invasiveness of all SRC cell lines
as previously described [21]. Briefly, a polycarbonate
membrane with 10- μm pores was uniformly coated
with a defined matrix. Both upper and lower wells of
the chamber were filled with RPMI. For CTGF treat-
ment, the RPMI was supplement with 50 ng, 100 ng, or
250 ng/mL of CTGF. Recombinant CTGF was obtained
from PeproTech Inc (Rocky Hill, NJ) (C-terminal pep-
tide; product# 120-19). SRC cells were seeded into
upper wells at a concentration of 5 × 10
5 cells per well.
After a 24-hour incubation in a humidified incubator at
37°C with 5% CO2, cells that had invaded through the
basement membrane were collected, stained, and
counted by light microscopy [22].
Tumor inductions in nude mice and tissue processing
T h eS R Cc e l l sw e r eg r o w nu n t i lt h e yw e r e8 0 %c o n f l u -
ent, the cells were then washed with PBS, and then cells
were removed from the plate using TrypLE Express
(GIBCO cat#: 12605-010) according to manufacturer’s
instructions. Following removal of SRC cells from plates,
the cells were washed with PBS, centrifuged, and resus-
pended in PBS. 5 × 10
6 cells were injected subcuta-
neously into the lower lumbar region of four-week old
nude mice (Males; Charles River, Strain code: 088). For
the control group, the SRC -LTC-MSCV-I-Hygro (cells
expressing the empty viral vector) were injected into 10
separate mice. For one experimental group, SRC-LTC-
MSCV-Thyb4-I-Puro cells were injected into 10 indivi-
dual mice. For the other experimental group, SRC-LTC-
MSCV-cFos-I-Puro cells were injected into an additional
10 individual mice.
Following the injection, the animals were monitored
twice weekly for 30 days. After 30 days the animals
were euthanized by CO2 gas inhalation followed by cer-
vical dislocation. Immediately following euthanization,
tumors and other tissues were frozen in liquid nitrogen
or placed in paraformaldehyde for histologic
examination.
Nude mice were selected for this study because pre-
vious experiments in our laboratory had demonstrated
t h a tt h eS R C - L T Cc e l ll i n eg r e wi nn u d em i c ew i t h o u t
host rejection. Since the SRC-LTC was modified with a
retrovirus, we wanted to reduce the chance that the
tumor cells would be rejected by the host immune
response. Previous experiments in our laboratory had
also indicated that the subcutaneous injection of SRC-
LTC cells (modified with retrovirus) into nude mice
w o u l dl e a dt ot h ef o r m a t i o no fp a l p a b l et u m o r si n4
weeks. Subcutaneous injection of SRC-LTC cell line into
rats resulted in slower tumor growth than those gener-
ated in nude mice. Palpable tumors were detected at 4
months in rats compared to less than 1 month in nude
mice. To limit experimental time, and to prevent the
rejection of tumor cells by the host, nude mice were
selected for the transplantation experiments with SRC-
LTC cells.
Statistical analysis
Significant differences in tag count among SAGE tag
libraries were determined using a Z-test (∝ = .05) [23].
When the significance level is set at 0.05, a z-value
greater than 1.96 is considered as a statistically signifi-
cant difference.
DNA methylation level data were analyzed with the
analysis of variance (ANOVA) method and mean DNA
methylation levels from three groups were compared
with the normal rat cartilage group and the resulting p-
values were adjusted using the Dunnett method. We
used statistical software SAS 9.1 and R to conduct ana-
lysis and generate figures. We attributed statistical sig-
nificance to p values ≤ 0.05 in all comparisons.
Significant pathways and their associated p-values
were determined using the pathway-mapping program
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way is a measure of its significance with respect to the
genes in a given data set and a reference set of genes
(containing all of the members of predetermined path-
way). P-values were calculated using the right-tailed
Fisher’s Exact Test, and the purpose of this test is to
analyze a data set to identify the pathways that contain
more genes from a given data set than would be
expected by random chance. Statistically significant,
non-random association is attributed to p values < 0.05
(see Ingenuity for more detailed explanations of the sta-
tistical analysis; http://www.ingenuity.com/).
Results
Tumor transplantation site influences tumor phenotype
Tumors were initiated by transplanting SRC tumor cells
subcutaneously or into the tibia of Sprague-Dawley rats.
The tumors exhibited different growth and histologic
characteristics depending on the tumor transplantation
site. Approximately 3 weeks following subcutaneous
transplantation, tumors were isolated and determined to
have an average weight of 35.05 g (Figure 1A). Three
weeks following tumor transplantation into the tibia the
tumors weighed an average of 75.22 mg (Figure 1A).
Transplantation of the SRC tumor into the tibia resulted
in bone destruction and tumor invasion into the sur-
rounding cortex of the bone (Figure 1B). In comparison,
the subcutaneous SRC tumors did not invade into sur-
rounding tissues. Therefore, as reported previously [8],
t h eS R Ct i b i at u m o rw a sc l a s s i f i e da sah i g h e rg r a d e
tumor than the subcutaneous (extraosseous) SRC
tumors.
Tumor transplantation into the tibia also led to the
formation of SRC tumors in the lungs of rats (50% of
animals; Figure 1C). No SRC lung tumors were detected
in the lungs of rats that had the SRC tumor trans-
planted subcutaneously.
Although 50% of the animals with the tibia SRC
tumor also developed lung SRC tumors, the latter most
likely resulted from colonization of tumor cells in the
lungs rather than metastasis. As pointed out before, ani-
mals that had their leg amputated immediately following
tumor transplantation did exhibit tumors in the lungs.
Hence, we do not refer to the SRC lung tumor as a
metastasis. Since chondrosarcoma does metastasize to
the lungs in humans, we reason the inclusion of the
SRC lung tumors in our analyses is justified in that it
might provide relevant information relating to chondro-
sarcoma development and progression.
Epigenetic analysis of SRC tumors
Epigenetic analyses were carried out to determine
if there was a difference in the DNA methylation
levels of the tumors that were initiated at different
transplantation sites. The methylation level of cytosines
in CpG dinucleotides of repetitive elements has been
used as a marker for assessment of genome-wide levels
of methylation [9,24]. Hence the Satellite 1 repetitive
element was selected as a methylation marker in our
study. Rat specific pyrosequencing assays were designed
to examine the methylation of Satellite 1 sequences
throughout the genome. Pyrosequencing was performed
on DNA isolated from control tissue, rat normal (articu-
lar) cartilage (RNC), and on SRC tumor tissues derived
from the different transplantation sites.
Pyrosequencing of rat satellite 1 revealed methylation
differences between the SRC tumors and rat normal car-
tilage, as well as among the SRC tumors at different
transplantation sites. Specifically, the SRC tumors exhib-
ited a lower level of methylation than the rat normal
cartilage (Figure 2). Amongst the SRC tumors, the sub-
cutaneous tumor and the tibia tumor had lower Satellite
1 methylation levels than the lung tumor (Figure 2).
These results demonstrate that the Satellite 1 DNA is
hypomethylated in SRC tumors compared to control tis-
sue. Our results also indicate that the transplantation
site can influence DNA methylation levels in SRC
tumors. Since the observed differences in methylation
level involved satellite 1 DNA sequences mapped
throughout the genome, it is likely that the observed
alterations in methylation may be indicative of other
changes in methylation that might accompany tumor
growth at different transplantation sites.
SAGE library description
Based on the aforementioned differences among the
SRC tumors, we hypothesized that tumors would also
exhibit significant differences in gene expression. To test
this hypothesis, SAGE was used to generate gene
expression profiles of the SRC tumors. SAGE profiles
were generated for rat normal cartilage, the subcuta-
neous SRC tumor, the tibia SRC tumor, and the SRC
lung tumor. Over 400,000 SAGE tags were generated
for this analysis. The total number of SAGE tags
sequenced and the number of unique tags in each
library are shown in Figure 3A.
Gene expression differences between normal cartilage
and the SRC tumors
The SRC tumors exhibited significantly different gene
expression profiles compared to that of normal rat carti-
lage (control tissue), and these gene expression changes
distinguish tumors from RNC (Figure 3B). Analysis of
the differentially expressed genes revealed changes in
several pathways that may be important to chondrosar-
coma tumorigenesis. (Figure 3C). The most significantly
altered pathway, “Skeletal and muscular system develop-
ment and function”, highlighted differences in gene
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Page 5 of 16Figure 1 Phenotype of the Swarm Rat chondrosarcoma varies based on tumor transplantation site. (A)Tumor weight following
transplantation into different sites. The average tumor weight and standard deviation are shown. The weight of the subcutaneous SRC tumor
was calculated from 6 animals. The tibia SRC tumor weight was calculated based on tibia tumors isolated from 14 separate animals. The lung
tumor weight represents the average weight of individual tumor nodules collected from 7 animals. The lung tumors were isolated from animals
that had SRC tumor transplanted into the tibia (7 of 14 animals had lung tumors). (B)Transplantation of the SRC tumor into the tibia of Sprague-
Dawley rats. Histologic micrograph at day 34 revealed increased tumor volume and invasion of the tumor into the bony cortex. Cells stained
with safranin O and fast green. (C)SRC tumors detected in the lung of a rat that had the SRC tumor transplanted into the tibia. Note the
presence of multiple SRC tumors. Lung tumors were detected in 50% of the animals that had the SRC tumor transplanted into the tibia. The
number of lung SRC tumors in a single animal ranged from 1 to 54 (average = 10). The average size of the tumors was 2 mm. No lung tumors
were detected in the animals with subcutaneous tumor transplants.
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matrix of both tumor cells and surrounding host cells.
Specifically, gene expression alterations were detected
for structural extracellular matrix genes (Figure 4A) and
for extracellular matrix modifying proteases (Figure 4B).
Changes to the extracellular matrix have prognostic
value in chondrosarcoma. Decreased expression of spe-
cific extracellular matrix molecules, as observed with the
SRC tumors compared to normal tissue (Figure 4A), has
been associated with high grade human chondrosarco-
mas [25]. Increased expression of specific proteases has
also been reported in human chondrosarcoma [26,27].
These results indicate that gene expression alterations
in the SRC tumors include changes also observed in
human chondrosarcoma, thus providing additional sup-
port to previous work demonstrating that the SRC
tumor model resembles human chondrosarcoma [7].
Transplantation site influences gene expression
Although most structural extracellular matrix genes
were expressed at lower levels in the SRC tumors than
in normal cartilage, closer analysis revealed changes in
gene expression that were unique to the SRC tumor at
each transplantation site (Figure 4A). Additionally, the
expression of specific proteases varied among tumors.
The observed alterations in the expression of proteases
among SRC tumors may thus represent changes that are
unique to each specific transplantation site (Figure 4B).
Further analysis of the SAGE data revealed that the
gene expression profiles of the tumors are unique to
their transplantation sites (Figure 5). Although each
SRC tumor originated from the same tumor source, sig-
nificant gene expression differences were detected
among the SRC tumors. Characterization of these differ-
ences revealed changes in the expression of genes
involved in regulating “Cellular Assembly and Organiza-
tion” (Figure 3C). Several genes related to cell motility
were upregulated in both the tibia and lung SRC tumors
(Figure 4C). The altered expression of cell motility-
related genes suggests that both the tibia and the lung
microenvironments may promote changes in the actin
cytoskeleton, which in turn may have a direct impact on
the invasiveness of SRC cells.
Endogenous thymosin-b4 expression in the SRC tumors
It is noteworthy that one of the genes identified in the
cell motility pathway, thymosin-b4, is significantly upre-
gulated in the tibia and lung SRC tumors (Figure 6A).
Thymosin-b4 is thought to play a role in the cytoskele-
tal organization of chondrocytes [28], and overexpres-
sion of thymosin-b4 may influence tumorigenicity and
metastasis [29].
Endogenous c-fos expression in the SRC tumors
The second most significantly altered pathway was “Cel-
lular Growth and Proliferation"(Figure 3C). More
detailed examination of this pathway identified several
differentially expressed genes that are components of
the AP-1 transcription factor complex (Figure 4D). AP-1
is a potent transcription factor that has multiple func-
tions in tumor cells [30]. One particular component of
AP-1, c-fos, was differentially expressed in both the tibia
and lung SRC tumors (Figure 6B). Expression of c-fos
has been investigated in human chondrosarcoma [31].
Overexpression of c-fos leads to the development of
chondrogenic tumors [32], and c-fos activity has been
associated with increased invasiveness of chondrosar-
coma cells [33].
Growth factor expression in the SRC tumors
Gene expression alterations in the SRC could promote
additional expression changes in the SRC cells and/or
may lead to altered expression in the surrounding host
cells. For example, changes in growth factor expression
were detected in the SRC tumors (Figure 4E). These
Figure 2 Transplantation microenvironment influences DNA
methylation in SRC tumors. Pyrosequencing revealed that Satellite
1 DNA was hypomethylated compared to DNA from normal rat
cartilage (control tissue). The satellite 1 DNA elements in the
subcutaneous SRC tumor and the tibia SRC tumor were
hypomethylated compared to the DNA in the lung SRC tumor. The
graph illustrates the average Satellite 1 DNA methylation calculated
from a pool of tissues from each transplantation site. For each
transplantation site, tumor tissue was pooled from at least 10
separate animals. Bars represent the average DNA methylation % of
technical replicates of the pooled tissue samples, and error bars
represent the standard deviation of these replicates. P-values are
indicated for comparisons between the specific sample and the
“Normal rat cartilage” sample using Dunnett method in the analysis
of variance (ANOVA). We attributed statistical significance to p
values ≤ 0.05.
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matrix where they have the potential to interact with
tumor and/or host cells. Taken together, these results
indicate that the tumor transplantation site has a signifi-
cant impact on the gene expression profile of the SRC
cells. These analyses provide insight into the interaction
between the SRC cells and the transplantation site, as
well as to the specific pathways that may contribute to
SRC tumorigenesis.
Functional analysis of differentially expressed genes
Overexpression of thymosin-b4 and c-fos
Based both on their differential expression (Figure 6)
and on their potential role in tumorigenesis, thymosin-
b4 and c-fos were selected for additional analyses. Thy-
mosin-b4 and c-fos were independently overexpressed
in a SRC cell line and the cell lines were used to induce
subcutaneous SRC tumors (Figure 7). Control tumors
were generated with SRC cells expressing an empty viral
vector, while the tumors in the experimental groups
were induced by injection of SRC cells overexpressing
either c-fos or Thymosin-b4. Histologically, the tumors
were classified as grade II chondrosarcomas (Figure 7B),
but certain phenotypic differences were observed
between the tumors.
Overexpression of thymosin-b4 resulted in the forma-
tion of the largest SRC tumors (Additional file 4). How-
ever, the size of the thymosin-b4-overexpressing-tumors
Figure 3 Summary and analyses of SAGE libraries. (A) Summary of SAGE tags generated from normal cartilage and the SRC tumors. The total
number of SAGE tags and the number of unique tags are listed for each SAGE library. (B) Heat map displaying the differentially expressed genes
between RNC and SRC tumor tissues. Rat normal (articular) cartilage has a unique expression profile when compared to the expression profiles
of the SRC tumors. The changes in gene expression may represent critical differences between normal cartilage cells and chondrosarcoma, and
they may also represent changes important for the development and progression of chondrosarcoma. Heat map displays the differentially
expressed genes that were expressed at a level of at least 25 tags in one library. For complete gene list see Additional file 2. Color bar illustrates
relative gene expression levels. (C) The list of differentially expressed genes was analyzed with the pathway-mapping program Ingenuity. The top
five functional pathways and their corresponding p-values are displayed in table (see “Methods” for description of p-value).
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Page 8 of 16varied among animals and the average tumor weight was
not statistically significantly different from that of
tumors derived from control cells (Figure 7A). Although
thymosin-b4 tumors did not exhibit a statistically signifi-
cant difference in size relative to the control tumors, it
should be noted that one of the mice (with the thymo-
sin-b4 tumor) died before the end of the in vivo experi-
ment (n = 10; 1 mouse died; see Additional file 4).
Histologic analysis of this animal revealed multiple lung
chondrosarcoma micrometastases. The finding of lung
metastasis in this animal is particularly intriguing due to
the fact that lung metastases have previously not been
detected following subcutaneous injection of SRC cells.
C-fos overexpression resulted in the formation of
tumors that were significantly smaller than control
tumors (Figure 7A and Additional file 4). Micrometasta-
sis was not detected in any animals with c-fos overex-
pressing tumors.
Figure 4 SAGE reveals gene expression differences between the SRC tumors and normal cartilage as well as gene expression
differences between SRC tumors. (A) Expression of extracellular matrix genes. (B) Expression of extracellular matrix modifying proteases. (C)
Expression of genes related to cell motility. (D) Expression of components of the AP-1 transcription factor complex. (E) Expression of growth
factors. The Heat map represents relative gene expression. Actual expression values are listed to the right of the heat map.
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Growth factor expression varied with the tumor trans-
plantation site (Figure 4E), but the functional conse-
quences of these changes are unknown. One growth
factor, CTGF (Connective Tissue Growth Factor), was
selected for further analysis because of its differential
expression and previously reported altered expression in
several cancers (including chondrosarcoma) [34-37]. To
test the influence of CTGF, the invasiveness of the SRC
cells was examined following incubation with varying
concentrations of CTGF. The lower doses of CTGF (50
a n d1 0 0n g / m L )d i dn o ts i g n i f icantly alter the invasive-
ness compared to that of control cells, but a higher con-
centration of CTGF resulted in a significant decrease
(30%) in SRC invasiveness (Figure 8).
Discussion
Tumor microenvironment is an important factor that
can influence the malignancy of SRC tumors [8].
Previous studies have characterized the histological
changes that accompany SRC tumor growth at different
transplantation sites [8]. However, little is known about
the gene expression changes that underlie the histologi-
cal changes. To address this issue, we examined the epi-
genetic and gene expression changes following SRC
growth at different tumor transplantation sites. Epige-
netic and gene expression changes were detected
between the SRC and normal tissue, and additional ana-
lysis revealed gene expression changes among SRC
tumors grown at different transplantation sites. Closer
examination of differentially expressed genes and subse-
quent functional analysis provided insight into the invol-
vement that specific genes may have in chondrosarcoma
tumorigenesis.
Subcutaneous SRC tumors ultimately produced the
largest tumors (Figure 1A). However, as it is the case
with human chondrosarcoma, tumor size does not
necessarily correlate with histologic grade [38]. The tibia
Figure 5 Tumor transplantation site significantly alters the gene expression profiles of the SRC tumors. Since the SRC tumors at different
transplant sites originated from the same source tumor, the unique SRC gene expression profiles at each transplant site are likely a result of
interactions in the microenvironment between tumor cells and host cells. For each gene expression comparison (A-C), a different tumor was
selected as a “reference sample"(highlighted in yellow). The gene expression of the “reference sample” was then compared with the gene
expression profiles of the other tumors. For each comparison, the upregulation/downregulation refers to the status of the genes in the
“reference sample” compared to the tumor samples. (A) Differential gene expression between the Subcutaneous SRC tumor (reference sample;
highlighted in yellow) and SRC tumors at the other transplantation sites (200 genes upregulated; 107 genes downregulated in the Subcutaneous
SRC tumor). (B) Differential gene expression between the Tibia SRC tumor (reference sample; highlighted in yellow) and the SRC tumors at the
other transplantation sites (106 genes upregulated; 108 genes downregulated in the tibia SRC tumor). (C) Differential gene expression between
the Lung SRC tumor (reference sample; highlighted in yellow) and the SRC tumors at the other transplantation sites (157 genes upregulated; 73
genes downregulated in the lung SRC tumor). Color bar illustrates relative gene expression levels. See “Methods” for additional description (Gene
expression comparisons between SRC tumors), and see Additional file 3 for complete data set and annotation of the genes presented within this
figure.
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Page 10 of 16tumor displayed increased tumor infiltration and bone
destruction over time (Figure 1B). Such invasive beha-
vior was not observed in the subcutaneous SRC tumors.
These findings suggest that the tibia SRC tumors have
increased invasive characteristics relative to the subcuta-
neous SRC tumors. These findings are also in agreement
with previous findings demonstrating that SRC trans-
plantation in the tibia results in tumor infiltration [7],
and changes in the malignancy of the SRC cells [8].
Epigenetic analysis of the SRC tumors revealed that
the SRC tumors are hypomethylated compared to nor-
mal rat cartilage. The epigenetic analysis also demon-
strated that the tumor transplantation site can influence
the DNA methylation levels of the SRC tumors. This
result supports previous observations suggesting that the
microenvironment may modulate epigenetic events in
solid tumors [39]. Although the impact of hypomethyla-
tion on the SRC cells is largely unknown, DNA hypo-
methylation has been documented to occur in several
types of cancer [40]. Most importantly, previous studies
have demonstrated that DNA hypomethylation may
have a significant impact on tumorigenesis [9,41,42].
In addition to affecting DNA methylation, the trans-
plantation sites had a considerable impact on the global
gene expression profiles of SRC tumors. Such expression
changes provide some insight to the molecular mechan-
isms underlying growth and progression of SRC tumors.
Furthermore, the SRC tumors exhibit a gene expres-
s i o np r o f i l et h a ti ss i g n i f i c a n t l yd i f f e r e n tf r o mt h a to f
normal rat cartilage, including a major decrease in the
expression of several extracellular matrix molecules (Fig-
ure 4A). Studies of human chondrosarcoma have indi-
cated that expression of collagen type II and aggregan
are indicative of a mature neoplasm with low recurrence
and low chance for metastasis [5]. A decrease in the
expression of extracellular matrix molecules, as observed
i nS R Ct u m o r s( F i g u r e4 A ) ,m a yr e p r e s e n tac h a n g ei n
the nature of the SRC tumors from a mature neoplasm
to a more aggressive less differentiated neoplasm.
The SRC tumors also expressed several matrix metal-
loproteases and cathepsins (Figure 4B). The expression
of these proteases varied depending on the SRC trans-
plantation site, but since these proteases alter the extra-
cellular matrix, their expression may have a significant
Figure 6 SAGE and quantitative RT-PCR confirm the expression of thymosin-b4 and c-fos in the SRC tumors. (A) Thymosin-b4 expression
in the SRC tumors (SAGE analysis top panel; quantitative RT-PCR bottom panel). (B) C-fos expression in the SRC tumors (SAGE analysis top panel;
quantitative RT-PCR bottom panel). SAGE and RT-PCR identified similar gene expression patterns for both thymosin-b4 and c-fos. Note the
increased expression of thymosin-b4 and c-fos in the tibia and lung SRC tumors. The graphical bars in the RT-PCR figure represent the average
expression ratio calculated on RNA that was collected from pooled tumor tissue. For RT-PCR at each transplantation site, tissue was pooled from
at least 10 separate tumors. SAGE data was normalized to 100,000 tags/library for analysis. In the SAGE graph, “*” indicates that the expression
levels of a specific sample are significantly different relative to the “Subcutaneous SRC tumor” sample (z > 1.96).
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Page 11 of 16impact on tumor progression. Altered expression of
matrix metalloproteases and cathepsins has previously
been reported in human chondrosarcoma [26,27], and
their expression may play an important role altering the
extracellular matrix and promoting tumor invasion.
Cathepsin K, for example, is thought to play a role in
human chondrosarcoma progression [26], and it is
expressed at highest levels in tibia SRC tumors (Figure
4B). Cathepsin K is a protease that has the ability to
degrade collagen type I [43], a major component of
bone. The expression of cathepsin K could explain the
degradation of bone that is observed with the tibia SRC
tumors (Figure 1B). The expression of cathepsin K com-
bined with the expression of other proteases may lead
to extracellular matrix degradation and subsequent SRC
tumor progression.
Further analysis of the SAGE data revealed additional
gene expression changes that may also contribute to
Figure 7 Tumor weight following induction of subcutaneous tumors with SRC cells overexpressing either thymosin-b4 or c-fos. Control
tumors were initiated with SRC cells that express the MSCV viral vector with no insert (pMSCV-I-Hygro vector). C-fos tumors were initiated with
SRC cells that overexpress c-fos (MSCV-cfos-I-Puro). Thymosin-b4 tumors were initiated with SRC cells that overexpress thymosin-b4 (MSCV-
Thyb4-I-Puro). Overexpression of c-fos resulted in the formation of tumors that were significantly smaller than control tumors. The bar represents
the average invasion indices of biologic replicates, and the error bars represent the standard deviation of the biologic replicates. ‘*’ Indicates that
the tumor weight is significantly different than the tumor weight of the control tumors (p-value <0.05 considered significant). n = 10 for control
tumors and c-fos tumors. n = 9 for thymosin-b4 tumors (one animal died prematurely and was found to have multiple chondrosarcoma lung
metastases). See Additional file 4 for complete list of tumor weights. (B) Photomicroscopy of histological sections obtained from SRC tumors (20
× magnification). Tumors induced from control cells (SRC cells expressing the empty viral vector), and from SRC cells overexpressing either
Thymosin-b4 (Thymosin-b4 tumor) or c-fos (C-fos tumor). Approximately 30 days following tumor induction animals were sacrificed and tumors
were removed for histology. Sections representative of each tumor are shown. All tumors were classified as histologic grade II chondrosarcomas.
The SRC cells are stained with Safranin O (red).
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Page 12 of 16chondrosarcoma tumorigenesis. Both the tibia SRC
tumor and the lung SRC tumor displayed elevated levels
of mRNAs regulating the actin cytoskeleton (Figure 4C),
and the SRC tumors also displayed elevated levels of
transcripts controlling cellular growth and proliferation
(Figure 4D). Overexpression of a cell motility related
gene, thymosin-b4, did not produce tumors that were
significantly larger than control tumors (Figure 7). How-
ever, overexpression of thymosin-b4 resulted in chondro-
sarcoma lung metastasis and subsequent death in one
animal. Since tumor size does not correlate with tumor
malignancy in human chondrosarcoma [38], the fact that
thymosin-b4 overexpressing tumors were not larger than
control tumors does not preclude the hypothesis that
they may have a greater malignant potential. It should be
emphasized, however, that although intriguing this obser-
vation has to be considered with great caution since it is
based on a single animal.
Although the function of thymosin-b4i nt h eS R Ci s
not known, high levels of thymosin-b4 have been
detected in human chondrosarcoma (National Cancer
Institute: SAGE Genie database). Overexpression of thy-
mosin -b4 has previously been shown to regulate moti-
lity and invasiveness in fibrosarcoma [29], and reports in
melanoma suggest that thymosin-b4c a ns t i m u l a t e
metastasis through the activation of cell migration and
angiogenesis [44]. The ability of thymosin-b4 to increase
tumor cell motility is thought to be related to its func-
tion in the regulation of the actin cytoskeleton [45], but
thymosin-b4 may have other functions in the SRC cells.
Thymosin-b4 can be secreted into the extracellular
matrix [46], and extracellular stimulation with thymo-
sin-b4 may lead to increased Ap-1 activity.
C-fos is a component of the AP-1 transcription factor
complex, and AP-1 is thought to play multiple roles in
tumorigenesis [30]. Overepxression of c-fos resulted in
the formation of tumors that were significantly smaller
than control tumors (Figure 7), which was not expected.
However, this result suggests that either directly or
indirectly c-fos’ activity does seem to influence tumor
growth. C-fos and AP-1 signaling have been associated
with chondrosarcoma development [47], and c-fos sig-
naling may influence the invasiveness of human chon-
drosarcoma cells [48,49].
The signaling mediators and effectors of c-fos/AP-1
interactions may vary depending on the microenviron-
ment of the transplantation site, and they may include
growth factors, cytokines, and/or other signaling mole-
cules. The expression analysis conducted in this study
revealed significant changes in growth factor expression
amongst the SRC tumors (Figure 4E). Most noteworthy,
VEGF, TGFB2 and CTGF, all of which are expressed in
human chondrosarcoma, were also found to be
expressed in SRC tumors. The potential function of
these growth factors range from cell motility, to cell
growth, to angiogenesis [50-52]. In this study, incuba-
tion with CTGF led to a decrease in the invasiveness of
the SRC cells (Figure 8). Although this result may
appear counterintuitive to a role for CTGF in tumor
progression, CTGF has recently been shown to enhance
cell adhesion of a human chondrosarcoma cell line
t h r o u g hi n t e r a c t i o nw i t hf i b ronectin (also expressed in
the SRC cells; Figure 4A) [53]. Regardless, the fact that
incubation with CTGF affected invasion, albeit in the
opposite direction to that expected, clearly points to its
activity being directly or indirectly associated with inva-
siveness in the SRC tumor model. Accordingly, we spec-
ulate that through interaction with fibronectin, CTGF
may promote adhesion and thus negatively affect moti-
lity. CTGF is expressed in normal lung cells [54,55], and
an intriguing hypothesis is that CTGF may play a role
in the adhesion of tumor cells in the lung. In addition
to a role in cellular adhesion, CTGF has previously been
shown to influence cell proliferation and angiogenesis
[56,57], but additional experiments are needed to deter-
mine if CTGF affects these pathways in the SRC.
T h em o d eo fg r o w t hf a c t o ri n d u c t i o ni nt h eS R C
tumors is not known, but growth factor induction could
be mediated through AP-1 signaling. Binding sites for
AP-1 have been identified in the promoter region of
CTGF [58] and TGFb-2 [59]. AP-1 is capable of
Figure 8 CTGF treatment decreases the invasiveness of SRC
cells. Invasiveness was measured in control SRC cells (SRC Control)
and in SRC cells treated with CTGF (50, 100, and 250 ng/mL) at the
start of the invasion assay. Twenty-four hours later, the invasiveness
was calculated for all samples and the results are displayed as
experimental sample compared to the untreated control SRC cells
(100% invasion). The bar represents the average invasion indices of
biologic replicates, and the error bars represent the standard
deviation of 3 biologic replicates.’*’ Indicates values that are
significantly different than the “SRC Control” sample (p < .05).
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Page 13 of 16activating the IGF-2 promoter [60], and the expression of
VEGF has previously been shown to be mediated through
AP-1 [61]. The induction of growth factors in the SRC
may, in part, be regulated by AP-1. Alternatively, changes
in AP-1 expression may also be influenced by growth fac-
tor expression [62-64].
Conclusions
Taken together, these experiments highlight the impor-
tance of the tumor microenvironment in SRC tumori-
genesis. Transplantation of a SRC tumor into different
microenvironments in the rat resulted in phenotypic
changes in the tumor. The changes in the phenotype
were accompanied by alterations in the transcriptome
and in the epigenome. DNA methylation patterns chan-
ged following tumor transplantation, indicating that the
transplantation site can affect the DNA methylation of
the SRC tumors. Despite originating form the same
tumor source, the SRC tumors also displayed expression
profiles unique to their transplantation sites. Subsequent
functional analysis shed some light into the mechanisms
of SRC tumorigenesis, and suggested that thymosin-b4
may contribute to the malignancy of SRC tumors.
Further research is needed to examine the function of
thymosin-b4 in chondrosarcoma, and to identify factors
that control its expression. For example, the promoter
region of the human thymosin-b4g e n ec o n t a i n saC p G
island [65], which indicates that DNA methylation could
play a role in the regulation of thymosin-b4. Addition-
ally, experiments are needed to determine how biologic
signaling at the transplantation site affects DNA methy-
lation, and to determine if these changes in DNA
methylation have an effect on SRC tumorigenesis.
Additional material
Additional file 1: Gene expression data generated with the SAGE
experiments. The SAGE data is presented as a table. The first row of the
table describes each column of the table. Each subsequent row
corresponds to a single SAGE tag. Each tag is identified by its 10 base-
pair nucleic acid sequence. The adjacent columns provide the expression
value for each tag in a given SAGE library. The raw expression data and
the normalized expression values are given for each SAGE library (for the
normalized data the tags were normalized to 100,000 tags/library). For
each SAGE tag, the Unigene number and gene name description are
given if known.
Additional file 2: Differentially expressed SAGE tags. Complete list of
differentially expressed genes obtained from the comparison of “Rat
Normal Cartilage” vs. all 3 SRC SAGE libraries ("Subcutaneous SRC tumor”,
“Tibia SRC tumor”, and “Lung SRC tumor”). The criteria for section was as
follows: z-value > 1.96 (for differential gene expression) and expression of
at least 25 tags in one SAGE library. The data is presented as a table. The
first row of the table describes each column of the table. Each
subsequent row corresponds to a single SAGE tag. Each tag is identified
by its 10 base-pair nucleic acid sequence. The adjacent columns provide
the expression value for each tag in a given SAGE library. For each SAGE
tag, the Unigene number and gene name description are given if
known.
Additional file 3: SAGE tag list of unique expression profiles.T h e
complete list of differentially expressed genes for the following
comparisons are presented in Appendix C: “Subcutaneous SRC tumor” vs.
“Tibia SRC tumor” and “Lung SRC tumor”, “Tibia SRC tumor” vs.
“Subcutaneous SRC tumor” and “Lung SRC tumor”, and “Lung SRC tumor
“ vs. “Subcutaneous SRC tumor” and “Tibia SRC tumor”. The criteria for
selection was as follows: z-value > 1.96 (for differential gene expression)
and expression of at least 25 tags in one SAGE library. The first row of
the table describes each column of the table. Each subsequent row
corresponds to a single SAGE tag. Each tag is identified by its 10 base-
pair nucleic acid sequence. The adjacent columns provide the expression
value for each tag in a given SAGE library. For each SAGE tag, the
Unigene number and gene name description are given if known.
Additional file 4: Summary of subcutaneous tumor weight
following transplantation of SRC cells that overexpress thymosin-b4
or c-fos. Tumors harvested 33 days following subcutaneous tumor
transplantation. Tumor weights are reported for control tumors,
Thymosin-b4 tumors, and c-fos tumors.
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